XML 47 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Quarterly Financial Data-Unaudited (Tables)
 12 Months Ended
Dec. 31, 2013
Consolidated Quarterly Financial Data-Unaudited  
Schedule of unaudited consolidated quarterly financial data

The following tables provide unaudited consolidated quarterly financial data for 2013 and 2012 (in thousands, except per share data):

 
   March 31, 2013   June 30, 2013   September 30, 2013   December 31, 2013  

U.S. Feraheme product sales, net(a)

   $ 15,578   $ 17,456   $ 19,347   $ 18,981  

License fee and other collaboration revenues          

     2,003     2,055     1,998     2,329  

Other product sales and royalties

     299     138     271     401  
                   
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total revenues

     17,880     19,649     21,616     21,711  

Cost of product sales

     2,942     3,145     2,547     3,326  

Gross margin

     14,938     16,504     19,069     18,385  

Operating expenses

     19,409     19,260     19,464     22,380  

Interest and dividend income, net

     271     256     246     278  

Gains on assets held for sale

     299     566     —     59  

Gains on investments, net

     6     26     4     4  
                   
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Net loss

   $ (3,895 ) $ (1,908 ) $ (145 ) $ (3,654 )
                   
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
                   

Net loss per share—basic and diluted

   $ (0.18 ) $ (0.09 ) $ (0.01 ) $ (0.17 )


 

 
   March 31, 2012   June 30, 2012   September 30, 2012   December 31, 2012  

U.S. product sales, net(a)

   $ 13,626   $ 14,094   $ 16,186   $ 14,381  

License fee and other collaboration revenues(b)

     1,753     16,592     1,566     6,564  

Other product sales and royalties

     101     326     -10     199  
                   
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total revenues

     15,480     31,012     17,742     21,144  

Cost of product sales

     2,646     3,224     4,323     4,027  

Gross margin

     12,834     27,788     13,419     17,117  

Operating expenses

     25,643     22,772     17,420     20,532  

Restructuring expenses(c)

     —     1,058     562     595  

Interest and dividend income, net

     393     338     295     260  

(Losses) gains on investments, net(d)

     —     (1,471 )   2     3  

Income tax benefit

     —     494     299     61  
                   
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Net income (loss)

   $ (12,416 ) $ 3,319   $ (3,967 ) $ (3,686 )
                   
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
                   

Net income (loss) per share—basic

   $ (0.58 ) $ 0.16   $ (0.19 ) $ (0.17 )

Net income (loss) per share—diluted

   $ (0.58 ) $ 0.15   $ (0.19 ) $ (0.17 )

        Quarterly loss per share totals differ from annual loss per share totals due to rounding.

        (a)   In each of the quarters ended September 30, 2013 and 2012, we revised our estimated Medicaid utilization rate, which resulted in a reduction of our estimated Medicaid rebate reserve related to prior year Feraheme sales of $0.6 million. In addition, in the first three quarters of 2012 we reduced our reserve for product returns by $2.2 million.

        (b)   During the quarters ended June 30, 2012 and December 31, 2012, we recognized $15.0 million and $5.0 million related to certain milestone payments we received from Takeda upon the EU marketing authorization of Rienso and the commercial launches of Feraheme/Rienso in Canada and the EU, respectively.

        (c)   In 2012 we carried out corporate restructurings pursuant to which we reduced our workforce and incurred charges related to employee severance and other related costs. See Note R.

        (d)   In June 2012, we sold our then remaining ARS portfolio and recognized a loss of approximately $1.5 million.